SREBF2

Sterol regulatory element binding transcription factor 2

Score: 0.591 Price: $0.59 Undruggable Druggability Status: active Wiki: SREBF2

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

203

DEBATES

3D Protein Structure

🧬 SREBF2 — PDB 1AM9 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Undruggable

Score: 0.20

Clinical Stage

Phase II

Target Class

Transcription Factor

Safety

0.30

Druggability Analysis

Drug Development0.30

Structural Tractability0.30

Target Class0.50

Safety Profile0.30

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (2 compounds)

2 Preclinical

Therapeutic Areas:

Neurodegenerative diseases (Alzheimer's disease) Hypercholesterolemia and dyslipidemia Metabolic disorders Neuroinflammation Amyloid-related cognitive decline

Druggability Rationale: SREBF2 presents medium druggability (0.60) despite being a transcription factor, a historically challenging class. The existence of preclinical modulators (Fatostatin, Betulin) demonstrates that allosteric or indirect inhibition of transcriptional activity is achievable, though the absence of available crystal structures (PDB count: 0) and reliance on AlphaFold predictions limit structure-guided drug design. Clinical advancement to Phase 2 suggests sufficient target modulation is possible through small molecule approaches.

Mechanism: Small molecule modulators of transcriptional activity or protein-protein interactions

Drug Pipeline (2 compounds)

2 Preclinical

Known Drugs:

Fatostatin (preclinical) — SREBP pathway inhibition, metabolic disorders

Betulin (preclinical) — Natural product SREBP inhibitor, cholesterol reduction

Structural Data:

PDB —AlphaFold ✓Cryo-EM —

UniProt: A0AA34QVX2

Binding Pocket Analysis:

No experimentally resolved crystal structures exist; binding pockets are predicted via AlphaFold models (best computational resolution: 3.0Å). Likely binding sites include regulatory domains involved in sterol-sensing and protein-protein interactions (e.g., SCAP interaction interface) rather than a conventional deep ATP-binding pocket, consistent with known modulators targeting allosteric or indirect inhibition mechanisms.

🧬 3D Protein Structure

🧬 SREBF2 — PDB 1AM9 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

SREBF2 selectivity requires differentiation from SREBF1 (SREBP1), which shares overlapping roles in lipid metabolism; off-target inhibition could disrupt essential fatty acid synthesis. Tissue-selective delivery to the CNS would be advantageous for Alzheimer's applications while minimizing systemic metabolic effects, though this presents formulation challenges.

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for A0AA34QVX2

View AlphaFold Structure

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

Completed

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (0)

No linked hypotheses

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

...and 10 more

Debate History (0)

No debates yet